Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. Jul/Aug 2017;11(4):256-265.
doi: 10.1097/ADM.0000000000000324.

Misuse of Novel Synthetic Opioids: A Deadly New Trend

Affiliations
Free PMC article
Review

Misuse of Novel Synthetic Opioids: A Deadly New Trend

Matthew P Prekupec et al. J Addict Med. .
Free PMC article

Abstract

: Novel synthetic opioids (NSOs) include various analogs of fentanyl and newly emerging non-fentanyl compounds. Together with illicitly manufactured fentanyl (IMF), these drugs have caused a recent spike in overdose deaths, whereas deaths from prescription opioids have stabilized. NSOs are used as stand-alone products, as adulterants in heroin, or as constituents of counterfeit prescription medications. During 2015 alone, there were 9580 deaths from synthetic opioids other than methadone. Most of these fatalities were associated with IMF rather than diverted pharmaceutical fentanyl. In opioid overdose cases, where the presence of fentanyl analogs was examined, analogs were implicated in 17% of fatalities. Recent data from law enforcement sources show increasing confiscation of acetylfentanyl, butyrylfentanyl, and furanylfentanyl, in addition to non-fentanyl compounds such as U-47700. Since 2013, deaths from NSOs in the United States were 52 for acetylfentanyl, 40 for butyrylfentanyl, 128 for furanylfentanyl, and 46 for U-47700. All of these substances induce a classic opioid toxidrome, which can be reversed with the competitive antagonist naloxone. However, due to the putative high potency of NSOs and their growing prevalence, it is recommended to forgo the 0.4 mg initial dose of naloxone and start with 2 mg. Because NSOs offer enormous profit potential, and there is strong demand for their use, these drugs are being trafficked by organized crime. NSOs present major challenges for medical professionals, law enforcement agencies, and policymakers. Resources must be distributed equitably to enhance harm reduction though public education, medication-assisted therapies, and improved access to naloxone.

Conflict of interest statement

The authors report no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Chemical structures of novel synthetic opioids. Each compound is represented as molecular formula (top), skeletal formula (left), and ball-and-stick model (right) (used with permission of Jessica Holland, 2016).

Similar articles

See all similar articles

Cited by 26 articles

See all "Cited by" articles

References

    1. Amlani A, McKee G, Khamis N, et al. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct J 2015; 12:54. - PMC - PubMed
    1. Armenian P, Olson A, Anaya A, et al. Fentanyl and a novel synthetic opioid U-47700 masquerading as street “Norco” in Central California: a case report. Ann Emerg Med 2017; 69:87–90. - PubMed
    1. Baumann MH, Partilla JS, Lehner KR. Psychoactive “bath salts”: not so soothing. Eur J Pharmacol 2013; 698:1–5. - PMC - PubMed
    1. Brandt SD, King LA, Evans-Brown M. The new drug phenomenon. Drug Test Anal 2014; 6:587–597. - PubMed
    1. Brittain RT, Kellett DN, Neat ML, et al. Proceedings: anti-nociceptive effects in N-substituted cyclohexylmethylbenzamides. Br J Pharmacol 1973; 49:158–159. - PMC - PubMed
Feedback